OVIT (OncoVista Innovative Therapies) Selling, General, & Admin. Expense: $2.65 Mil (TTM As of Sep. 2015)

OncoVista Innovative Therapies  (OTCPK:OVIT) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.

OncoVista Innovative Therapies Selling, General, & Admin. Expense Related Terms

The historical data trend for OncoVista Innovative Therapies's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Selling, General, & Admin. Expense Chart

OncoVista Innovative Therapies Annual Data
	Trend	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14
Selling, General, & Admin. Expense		Get a 7-Day Free Trial					1.95	1.04	0.88	0.62	1.88

OncoVista Innovative Therapies Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Selling, General, & Admin. Expense	Get a 7-Day Free Trial															0.16	1.46	0.11	0.93	0.16

OVIT vs RSPI, HSTC, CAPS: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoVista Innovative Therapies Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Selling, General, & Admin. Expense falls into.

OncoVista Innovative Therapies Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Business Description